StockTitan

@stocktitan.net

2 weeks ago

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder Clearmind Medicine (Nasdaq: CMND) reported successful ongoing treatment of participants in the third cohort of its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder (AUD) as of March 19, 2026. U.S. sites at Yale and Johns Hopkins continue treatment with no serious adverse events reported to date.The multinational, multicenter study evaluates safety, tolerability, pharmacokinetics and preliminary efficacy of the company’s non-hallucinogenic, MEAI-based oral candidate in patients with moderate to severe AUD.

#CMND Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

2 weeks ago

Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies Clearmind Medicine (Nasdaq: CMND) announced publication of six patents in Hong Kong on March 17, 2026 covering proprietary combination therapies that integrate Palmitoylethanolamide (PEA) with six psychedelic compounds.The patents protect formulations combining PEA with MDMA, LSD, ketamine, ibogaine, psilocybin, and DMT, and reflect a sourcing partnership with NeuroThera Labs. The company describes these combinations as intended to enhance therapeutic potential, safety, tolerability, and neuroplasticity profiles for mental health and neurological indications.

#CMND Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

3 weeks ago

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy Clearmind Medicine (Nasdaq: CMND) on March 13, 2026 filed a patent application with Hong Kong IPD for a combination therapy pairing proprietary MEAI with Palmitoylethanolamide (PEA) to treat major depressive disorder (MDD).The filing notes the PEA supply via a partnership with NeuroThera Labs (TSXV: NTLX), a SciSparc subsidiary, and positions the MEAI-PEA synergy as a non-hallucinogenic neuroplastogen approach targeting an MDD market projected above $25 billion by 2030.

#CMND Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

3 weeks ago

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve

#CMND Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

3 weeks ago

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease Clearmind Medicine (Nasdaq: CMND) announced on March 10, 2026 the publication of an international PCT patent application for a novel, non-hallucinogenic combination therapy pairing MEAI with Palmitoylethanolamide (PEA) targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD).The company cites a collaboration with NeuroThera Labs and notes market context: global weight-loss drugs valued at ~$37B in 2025 and forecast to reach ~$226B by 2035. The filing is a patent publication, not a granted patent or clinical efficacy readout.

#CMND Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

1 month ago

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval Clearmind Medicine (Nasdaq: CMND) reported that an independent Data and Safety Monitoring Board unanimously cleared progression of its FDA-approved Phase I/IIa trial of CMND-100 in Alcohol Use Disorder after a second interim review on March 4, 2026.The DSMB found additional topline safety data from the second cohort — which used twice the dose of cohort one — acceptable and recommended moving to a third cohort dosed at 80 mg. The multinational, multicenter study continues to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy.

#CMND Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

2 months ago

Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025 Clearmind Medicine (Nasdaq: CMND) announced it filed its Annual Report on Form 20-F for the fiscal year ended October 31, 2025 with the U.S. Securities and Exchange Commission on January 20, 2026. The report is available on the SEC website and on Clearmind's Investor Relations website. Shareholders may request free copies by contacting Clearmind's Investor Relations Department via the provided email address. The filing relates to the company's clinical-stage work on neuroplastogen-derived therapeutics.

#CMND Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

2 months ago

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100 Clearmind Medicine (Nasdaq: CMND) announced that all patients in the second cohort of its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder have completed treatment per protocol.The second cohort included 6 patients enrolled across multinational sites including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. This milestone follows DSMB approval to continue enrollment and builds on the first cohort’s reported favorable safety profile and preliminary signals of reduced cravings and withdrawal. Topline results from cohort two are expected in the coming months as the study continues to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy.

#CMND Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

3 months ago

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth Clearmind Medicine (Nasdaq: CMND) reviewed 2025 progress, highlighting clinical and intellectual property advances for its lead candidate CMND-100, an oral non-hallucinogenic MEAI-based therapy for Alcohol Use Disorder (AUD).Key 2025 points: first-in-human dosing and completed enrollment/treatment for cohort 1, completed dosing for cohort 2, DSMB unanimous approval to continue after interim safety review, multinational site activations at Yale, Johns Hopkins and Israeli centers, and multiple international patent filings across neuroplastogen indications.

#CMND Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

3 months ago

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100 Clearmind Medicine (Nasdaq: CMND) announced completion of patient enrollment for the second cohort in its FDA-approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder on Dec. 16, 2025. The six-patient cohort was recruited rapidly across three clinical sites: Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.The trial is multinational and will assess safety, tolerability, pharmacokinetics, and preliminary efficacy in moderate-to-severe AUD. Dosing for the second cohort is expected to start shortly, and topline results are anticipated in the coming months. The announcement references encouraging topline safety and preliminary efficacy signals from the first cohort.

#CMND Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

3 months ago

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment Clearmind Medicine (Nasdaq: CMND) announced a peer-reviewed review published Dec 2, 2025 in Current Addiction Reports evaluating its proprietary candidate MEAI (CMND-100) for alcohol use disorder (AUD).The review, led by experts including Anahita Bassir Nia from Yale, examines MEAI's pharmacology, receptor interactions, preclinical efficacy, and emerging clinical observations, and positions MEAI as a potential AUD treatment with milder subjective effects and lower cardiovascular, neurotoxicity, and abuse potential than MDMA and classic psychedelics. Recreational dosing reported at 1–2 mg/kg orally with positive effects around 4 hours is cited. The review notes no serious adverse events reported by recreational users but highlights there are no published human adverse‑effect studies to date, while receptor data suggest reduced 5-HT2A/2B/2C activity and no 5-HT2B calcium flux agonism.

#CMND Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

3 months ago

Clearmind Medicine Announces 1-for-40 Reverse Share Split Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems,

#CMND Clearmind Medicine Announces 1-for-40 Reverse Share Split

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

3 months ago

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health

#CMND Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

4 months ago

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder Clearmind Medicine (Nasdaq: CMND) announced the first participant was enrolled and dosed with CMND-100 at Hadassah-University Medical Center in Jerusalem on Dec. 2, 2025 as part of its multinational Phase I/IIa trial for Alcohol Use Disorder (AUD).The trial evaluates safety, tolerability, pharmacokinetics and preliminary efficacy of the company’s MEAI-based oral candidate. Recent top-line results from the first cohort were described as positive and the Data and Safety Monitoring Board gave a unanimous recommendation to continue, supporting trial momentum across active sites.

#CMND Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

4 months ago

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial Clearmind Medicine (Nasdaq: CMND) announced three clinical milestones for its MEAI-based oral therapy CMND-100 targeting Alcohol Use Disorder: positive top-line safety and preliminary efficacy data from the trial's first cohort of six participants (reported Nov 18, 2025); a unanimous independent DSMB recommendation to continue following an unblinded safety review (Nov 24, 2025); and activation of a new Israeli site, Tel Aviv Sourasky Medical Center, with first patient enrolled (Nov 25, 2025), joining Yale, Johns Hopkins and Hadassah sites. The Phase I/IIa trial evaluates safety, tolerability, pharmacokinetics and preliminary efficacy and the new site may accelerate multinational recruitment for subsequent phases.

#CMND Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

4 months ago

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial Clearmind Medicine (Nasdaq: CMND) announced that Tel Aviv Sourasky Medical Center (TASMC) has enrolled the first patient in the company’s FDA-approved multinational Phase I/IIa trial of CMND-100 for Alcohol Use Disorder (AUD) on Nov 25, 2025. TASMC, led by Prof. David Zeltser, is now fully activated and joins sites including Yale, Johns Hopkins, and Hadassah.The trial is assessing safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, a non-hallucinogenic oral MEAI-based compound. Recent top-line data from the first completed cohort reported excellent safety and adherence with no serious adverse events. Management said TASMC enrollment accelerates global recruitment efforts.

#CMND Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

4 months ago

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review Clearmind Medicine (Nasdaq: CMND) announced that its independent Data and Safety Monitoring Board completed an interim review of the FDA‑approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder on Nov 24, 2025 and unanimously recommended the trial continue.Key interim findings from the initial dosing cohort included no serious adverse events, general good tolerability, and high adherence to the dosing regimen and study protocol. The multinational trial evaluates safety, tolerability, pharmacokinetics, and preliminary efficacy in reducing alcohol cravings and consumption.

#CMND Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

4 months ago

Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0)

#CMND Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

4 months ago

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder Clearmind Medicine (NASDAQ: CMND) announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa trial of CMND-100, a non-hallucinogenic MEAI-based oral candidate for Alcohol Use Disorder (AUD), on November 18, 2025. The six-patient first cohort showed a favorable safety profile with no serious adverse events reported and generally good tolerability. Investigators also reported high treatment adherence, supporting feasibility and patient acceptability. Dosing was completed at Johns Hopkins and Yale under the multicenter, single- and multiple-dose protocol; the company will continue evaluation in subsequent cohorts toward a full data readout.

#CMND Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

4 months ago

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems,

#CMND Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

4 months ago

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems,

#CMND Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

4 months ago

Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of

#CMND Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

4 months ago

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage

#CMND Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

4 months ago

Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency Clearmind Medicine (Nasdaq: CMND) received a Nasdaq Listing Qualifications notice dated November 3, 2025, for failure to meet Nasdaq Listing Rule 5550(b)(1), which requires $2,500,000 minimum stockholders' equity.The company reported $1,065,668 of stockholders' equity as of its Form 6-K for the three and nine months ended July 31, 2025. Clearmind has 45 calendar days (until December 18, 2025) to submit a compliance plan; Nasdaq may grant up to 180 days total if the plan is accepted.Management is evaluating options to regain compliance, including conversion of previously announced convertible promissory notes (up to $10,000,000). To date $1,045,062 of notes converted into 885,000 common shares on October 30–31, 2025, and the company expects further conversions could demonstrate compliance, though acceptance is not assured.

#CMND Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

5 months ago

Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing Clearmind Medicine (NASDAQ: CMND) filed a patent application in South Korea covering compositions of its proprietary compound 5-methoxy-2-aminoindane (MEAI) for the treatment of depression on November 5, 2025. The filing is described as strengthening Clearmind’s global IP portfolio for MEAI, a non-hallucinogenic neuroplastogen intended to modulate serotonin pathways, promote neuroplasticity, and alleviate depressive symptoms without psychedelic effects.Preclinical studies are reported to show MEAI’s potential to enhance mood regulation and reduce anhedonia. The company says the expanded IP now includes protections across multiple jurisdictions as it prepares for further clinical development and commercialization.

#CMND Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing

www.stocktitan.net/news/CMND/clearmind-expa...

StockTitan

@stocktitan.net

5 months ago

Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy Clearmind Medicine (NASDAQ: CMND) announced publication of a U.S. patent application on Oct 31, 2025 expanding intellectual property coverage for its non‑hallucinogenic neuroplastogen MEAI (5‑methoxy‑2‑aminoindane) for treatment of cocaine addiction.The filing emphasizes MEAI's proposed mechanism—modulation of serotonin and dopamine pathways—and positions the program against a disorder with no FDA‑approved pharmacological treatments. The release cites a global market estimate of $1.36 billion in 2025 growing to $2.03 billion by 2032, and frames the application as strengthening Clearmind's IP portfolio and pipeline strategy for non‑hallucinogenic neuroplastogens.

#CMND Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

5 months ago

Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder Clearmind Medicine (Nasdaq: CMND) announced completion of treatment for the first cohort in its FDA‑approved Phase I/IIa trial of CMND‑100, an oral MEAI‑based candidate for Alcohol Use Disorder (AUD). Six patients have been enrolled and dosed so far, including two at Johns Hopkins and four at Yale; two additional sites in Israel are activated. The multinational, single‑ and multiple‑dose trial will assess safety, tolerability, and pharmacokinetics and explore preliminary efficacy signals such as reductions in alcohol cravings and consumption. The release cites a market projection rising from ~$13.2B (2024) to ~ $20B by 2032, highlighting commercial opportunity. Trial registry: NCT05913752.

#CMND Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

5 months ago

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder Clearmind Medicine (Nasdaq: CMND) enrolled the last patient in the first cohort of its FDA‑approved Phase I/IIa trial of CMND-100 for Alcohol Use Disorder on Oct 21, 2025. Six patients completed enrollment: two at Johns Hopkins and four at Yale. The multinational, multicenter, single‑ and multiple‑dose study will assess safety, tolerability, and pharmacokinetics and explore preliminary efficacy signals such as reductions in alcohol craving and consumption. All participants must want to reduce or stop drinking. Two additional sites in Israel are being activated to support further enrollment. Trial registration: NCT05913752.

#CMND Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

www.stocktitan.net/news/CMND/clearmind-medi...

StockTitan

@stocktitan.net

5 months ago

Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems,

#CMND Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

www.stocktitan.net/news/CMND/clearmind-medi...